




The relative strengths and weaknesses of Arbutus Biopharma Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arbutus Biopharma Corp compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 87% points. The greatest weakness of Arbutus Biopharma Corp is the variable Research and Development, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 285%, being 72% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	132,027
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,487
Liabilities, Non-Current	1,343
Other Assets	7,700
Other Compr. Net Income	2,067
Other Expenses	69
Other Liabilities	14,553
Other Net Income	5,254
Other Revenues	18,141
Property and Equipment	4,674
Research and Development	73,700
Selling, General and Administrative Expense	22,475

Output Variable	Value in 1000 USD
Assets	144,401
Liabilities	38,383
Expenses	96,244
Revenues	18,141
Stockholders Equity	106,018
Net Income	-72,849
Comprehensive Net Income	-71,816
BaseVar	152,245
ECR before LimitedLiability	174%
Economic Capital Ratio	285%